The efficacy of several selective PI3K/Akt/mTOR inhibitors has been investigated on both AML cell lines and AML primary cells using mTOR inhibitors as single agents or in association with chemotherapy (Table 1). This evidence concerns the gene PIK3CB and acute myeloid leukemia.